Why the Reference Specimen Changes a Roadside Cannabis Test Accuracy Claim

A roadside cannabis test's sensitivity and specificity depend on what it is compared with. Agreement with laboratory oral-fluid THC testing is a different claim from agreement with blood THC testing. Neither comparison automatically validates the test for functional impairment.

The reference defines a true positive

Wennberg and colleagues' systematic review included 101 studies of roadside screening compared with laboratory blood or oral-fluid cannabinoid tests. In that framework, a true positive meant agreement between the screening test and the chosen reference. It did not mean that an independent driving assessment had proved impairment. The reference matrix and cannabinoid threshold are therefore part of the accuracy claim.

Test rankings changed with the comparison

Against blood laboratory tests, oral-fluid screens generally had higher specificity and lower sensitivity than urine tests. Compared with observational tests, oral-fluid screening generally had higher sensitivity and similar specificity against the laboratory references. These are comparative patterns, not a declaration that every device performs equally well. Sensitivity varied, and imprecise estimates prevented definitive conclusions about the apparent leading instruments.

A matrix mismatch can be scientifically meaningful

An oral-fluid screen and a blood reference sample different biological materials. Discordance can reflect timing, thresholds and matrix-specific behavior as well as screening performance. The review notes that detecting THC presence across the two matrices differs from predicting one concentration from the other. A percentage copied without its reference method leaves readers unable to tell what the test was validated to detect.

Interpreting the evidence

This review searched the literature through March 2020; it is not a current ranking of all devices. For any claimed accuracy figure, retain the reference specimen, threshold and study population, and distinguish cannabinoid detection from assessment of driving ability.

Related reading: what functional driving tests are designed to establish.

Research reference

Erica Wennberg; Sarah B. Windle; Kristian B. Filion; et al. (2023). Roadside screening tests for cannabis use: A systematic review. Heliyon. doi:10.1016/j.heliyon.2023.e14630. Evidence basis: review/commentary abstract and selected explanatory passages.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

An Endogenous Pain Pathway Worked Independently of Endocannabinoid Mechanisms in Rodents

A rodent study found pain-related benefits from activating an endogenous adenosine pathway independently of opioid and endocannabinoid mechanisms. Endogenous pain modulation is therefore not automatically evidence of cannabinoid-receptor involvement. The intervention targeted adenosine signaling Researchers increased endogenous adenosine through kinase inhibition and separately tested a selective A3-receptor agonist. Receptor blockade…

Spread the love

Read Article: An Endogenous Pain Pathway Worked Independently of Endocannabinoid Mechanisms in Rodents

Cannabis in a Mixed-Drug Fatality Series: Hair and Blood Answer Different Exposure Questions

A Danish methadone-fatality study reported extensive mixed-drug exposure, including cannabis, and used segmental hair analysis to extend the exposure history beyond blood testing. That additional history was not proof of simultaneous intoxication from every listed substance. The two matrices supplied different information The study examined fatalities with both blood and…

Spread the love

Read Article: Cannabis in a Mixed-Drug Fatality Series: Hair and Blood Answer Different Exposure Questions

A Refractory Cancer-Pain Review’s Cannabinoid Option Was Not an Evidence-Based Ranking of Add-On Treatments

A 2015 review included cannabinoids among options for refractory cancer pain while describing weak benefit evidence across the reviewed drug strategies. Inclusion on a treatment-options list did not establish superiority or a favorable outcome for every patient. Refractory pain was a specific clinical question The review concerned pain not adequately…

Spread the love

Read Article: A Refractory Cancer-Pain Review’s Cannabinoid Option Was Not an Evidence-Based Ranking of Add-On Treatments

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us